1051899-73-0

Basic information

• Product Name: (3-Amino-2-fluorophenyl)methanol
• Synonyms: (3-Amino-2-fluorophenyl)methanol;(3-Amino-2-fluorophenyl)methanol, 2-Fluoro-3-(hydroxymethyl)aniline;3-Amino-2-fluorobenzyl alcohol;(3-Amino-2-fluorophenyl)
• CAS NO: 1051899-73-0
• Molecular Formula: C₇H₈FNO
• Molecular Weight: 141.1429232
• Mol File: 1051899-73-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 272.4±25.0 °C(Predicted)
• Appearance: /
• Density: 1.286±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 14.05±0.10(Predicted)
• CAS DataBase Reference: (3-Amino-2-fluorophenyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (3-Amino-2-fluorophenyl)methanol(1051899-73-0)
• EPA Substance Registry System: (3-Amino-2-fluorophenyl)methanol(1051899-73-0)

Safety Data

• Hazardous Substances Data: 1051899-73-0(Hazardous Substances Data)

Usage

Uses

(3-Amino-2-fluorophenyl)methanol is used as a reactant in the preparation of pyrazolylthiadiazolamine derivatives for the treatment of tuberculosis.

Upstream product

• 946126-95-0 (2-fluoro-3-nitrophenyl)methanol 
• 317-46-4 2-fluoro-3-nitro-benzoic acid 
• 914223-43-1 3-amino-2-fluoro benzoic acid 

Downstream Products

• 1051899-74-1 (3-(2-chloropyrimidin-4-ylamino)-2-fluorophenyl)methanol 
• 1251930-00-3 ethyl [2-fluoro-3-(hydroxymethyl)phenyl]carbamate 
• 1251930-02-5 ethyl (3-{[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1H-pyrazol-1-yl]methyl}-2-fluorophenyl)carbamate 
• 1251930-27-4 ethyl (3-{[5-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1H-pyrazol-1-yl]methyl}-2-fluorophenyl)carbamate 
• 1251930-10-5 ethyl {3-[(3-amino-1H-pyrazol-1-yl)methyl]-2-fluorophenyl}carbamate 
• 1251930-01-4 ethyl [3-(bromomethyl)-2-fluorophenyl]carbamate 

Relevant articles and documents

(PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS

A compound of Formula (I) wherein: either X is N and Y is CR5 or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and Me; R2 is selected from H, OH, OMe and Me; each R3 is independently selected from C1-3alkyl, F, Cl, Br, CF3 and NH2; R4 is selected from Me, CF3, NO2 and CHF2; R5 is selected from H, Me and CHF2; R6 is selected from H and Me; and p is 0-3, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.